KDC-MN-372 – Kodiac biolabs

Plain-language summaryIntrigue 70 / 100

Edaravone is a small molecule that mops up free radicals (reactive oxygen species that damage neurons during stress). Mitsubishi-Tokyo developed it in Japan, where it was approved in 2001 for acute ischemic stroke. The FDA later approved it in 2017 for ALS based on a Japanese phase 3 trial showing slowed functional decline in early-stage patients with preserved breathing capacity. The benefit is real but modest, and only a subset of ALS patients qualify. An oral version arrived in 2022, replacing the original IV-only protocol. Edaravone is the canonical free-radical scavenger drug in neurology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

FDA-approved ROS scavenger for ALS and stroke, useful reference compound but not frontier research

Look, edaravone has a genuinely interesting story on paper: a pyrazolone compound that scavenges peroxyl and hydroxyl radicals, approved in Japan for acute ischemic stroke back in 2001 and then FDA-approved for ALS in 2017 under Radicava. Thats a real clinical track record. The oral formulation (Radicava ORS) added in 2022 improved the accessibility picture considerably. So why aren’t we more excited about it?

The mechanism is the issue. Free radical scavenging as a primary MoA is one of those ideas that looks elegant until you zoom out and count how many antioxidant compounds have failed to translate in neurodegeneration trials. Oxidative stress is absolutely real in ALS pathology, and edaravone’s Japanese phase 3 (MCI186-19) did show slowed functional decline on the ALSFRS-R. But that trial enrolled a carefully selected subset: early disease, preserved respiratory function, no comorbidities that would confound. Whether the signal holds in broader populations is genuinely contested. The Japanese and US regulatory bodies accepted it; a meaningful portion of neurologists remain unconvinced of real efficacy in typical ALS patients.

As a research tool, edaravone’s strongest role is probably as the canonical ROS scavenger reference compound in neurology and ischemic injury models. If you’re running oxidative stress assays in neural cell lines or rodent stroke preparations, it’s a clean, well-characterized probe with predictable pharmacokinetics (plasma half-life around 4.5 hours). That utility is real. It’s not going to answer questions that N-acetylcysteine or MnTBAP couldn’t also probe, but the regulatory-grade characterization makes it a credible positive control in publication-facing work.

What we like: the ALS approval gives investigators a legitimate clinical hook, and edaravone is one of only two approved pharmacological options for the disease (alongside riluzole), which means it gets used in the field whether researchers are excited by the mechanism or not. The transition to oral dosing also solves some practical barriers for repeat-exposure study designs.

What we don’t like: free radical scavenging is not a frontier mechanism. That’s been the central critique of the entire antioxidant therapeutic category for decades. The subset-specificity of the phase 3 data makes translational extrapolation genuinely uncertain, and the compound itself doesn’t open any research question that other tools can’t address. Honestly, edaravone sits in the ‘approved tool with modest novelty’ bucket. Researchers in ALS biology will have it in their toolkit by necessity; investigators outside that specific indication don’t have strong reason to prioritize it over more targeted probes.

Novelty: 30
Mechanism promise: 28
In-category differentiation: 42
Evidence quality: 60
Translational signal: 60
Research bench value: 55

Rationale Edaravone earns its novelty and mechanism scores from a mature, crowded antioxidant class with a poor track record in broader neurodegeneration; the ALS approval via MCI186-19 is real but the carefully selected subset blunts translational confidence. Evidence and translational scores are lifted by FDA approval, but the compound firmly occupies ‘approved workhorse’ territory rather than anything a frontier investigator would reprioritize around.

Free radical scavenger

A pyrazolone free radical scavenger; approved in Japan and the US for amyotrophic lateral sclerosis (ALS) and acute ischemic stroke.

Abstract

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; CAS 89-25-8; molecular formula C10H10N2O; molecular weight 174.20) is a pyrazolone free radical scavenger developed at Mitsubishi-Tokyo Pharmaceuticals. Originally approved in Japan in 2001 for acute ischemic stroke (Radicut), and in 2017 approved by the FDA for amyotrophic lateral sclerosis (Radicava). Mechanism: edaravone scavenges peroxyl, hydroxyl, and other reactive oxygen species, reducing oxidative damage to neurons and the surrounding glia in the affected region. The ALS approval was supported by a Japanese phase 3 trial (MCI186-19) demonstrating slowed functional decline (ALSFRS-R score) in a subset of patients with early disease and preserved respiratory function. Initially IV-only; an oral formulation (Radicava ORS) was approved in 2022. Plasma half-life is approximately 4.5 hours. Used as the canonical free radical scavenger in neurology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-372Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-372

Edaravone

Abstract

Read the full monograph